HTG Molecular Diagnostics, Inc. (HTGM) Upgraded at Zacks Investment Research
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The firm currently has a $2.50 target price on the medical research company’s stock. Zacks Investment Research‘s target price suggests a potential upside of 14.68% from the stock’s previous close.
According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “
Other research analysts also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of HTG Molecular Diagnostics in a research report on Wednesday, November 8th. ValuEngine upgraded shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $5.25.
HTG Molecular Diagnostics (NASDAQ:HTGM) opened at $2.18 on Wednesday. HTG Molecular Diagnostics has a 52-week low of $1.20 and a 52-week high of $13.25.
In related news, major shareholder Holdings A/S Novo sold 1,149,813 shares of the stock in a transaction that occurred on Friday, August 25th. The shares were sold at an average price of $1.81, for a total transaction of $2,081,161.53. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 1,661,889 shares of company stock worth $3,077,980. 7.60% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Granahan Investment Management Inc. MA raised its position in HTG Molecular Diagnostics by 488.3% in the third quarter. Granahan Investment Management Inc. MA now owns 416,608 shares of the medical research company’s stock worth $708,000 after acquiring an additional 345,798 shares during the period. Vanguard Group Inc. raised its position in HTG Molecular Diagnostics by 38.9% in the second quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock worth $359,000 after acquiring an additional 37,841 shares during the period. Finally, UBS Group AG bought a new position in HTG Molecular Diagnostics in the first quarter worth approximately $137,000. Institutional investors and hedge funds own 19.99% of the company’s stock.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.